Go Deep
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,872 | -2.8 | 1.44 | 0.00 | 1,143.76 |
| Oct 2026 | 20,917 | -2.7 | 1.42 | 0.00 | 1,124.18 |
| Oct 2026 | 20,872 | -2.8 | 1.44 | 0.00 | 1,140.48 |
| Oct 2026 | 21,069 | -2.6 | 1.35 | 0.00 | 1,067.44 |
| Oct 2026 | 20,984 | -2.7 | 1.39 | 0.00 | 1,098.92 |
| Oct 2026 | 20,779 | -2.9 | 1.48 | 0.00 | 1,171.93 |
| Oct 2026 | 20,806 | -2.8 | 1.47 | 0.00 | 1,159.58 |
| Oct 2026 | 22,085 | -1.7 | 0.89 | 0.00 | 703.21 |
Avalo Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 59,000.0 | 0.0 |
| Net Profit | -36,358,000.0 | -19,630,000.0 | -13,720,000.0 | -30,625,000.0 |
| EPS | -0.8 | -1.0 | — | -2.2 |
Avalo Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 59,000.0 | 441,000.0 | 1,924,000.0 | 18,051,000.0 | — |
| Net Profit | -78,259,000.0 | -35,129,000.0 | -31,544,000.0 | -41,658,000.0 | — |
| EPS | -5.8 | -7.9 | -113.6 | -1,063.2 | — |
Avalo Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 116,458,000.0 | 150,732,000.0 | 20,993,000.0 | 33,367,000.0 | — |
| Total Liabilities | 33,409,000.0 | 17,700,000.0 | 13,689,000.0 | 44,282,000.0 | — |
| Total Equity | 83,049,000.0 | 133,032,000.0 | 7,304,000.0 | -10,915,000.0 | — |
Owes vs Owns
Avalo Therapeutics, Inc. owed $0.09 for every $1 it owned in Jun 2026, down from $1.33 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.09× | 0.29× | 0.12× | 0.65× | 1.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Avalo Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 84.4%Intangible assets 9.0%Other assets 6.1%
How it's funded — Dec 2025
Other liabilities 28.2%Shareholders' equity 71.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 98.3 | 134.5 | 7.4 | 13.2 |
| Receivables | 0.0 | 0.6 | 0.1 | 1.9 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.5 | 1.2 | 2.0 | 2.4 |
| Intangible assets | 10.5 | 10.5 | 10.5 | 14.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 7.2 | 3.9 | 1.0 | 1.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.4 | 0.6 | 0.5 | 5.9 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 13.5 |
| Payables | 0.1 | 0.3 | 0.4 | 2.9 |
| Other liabilities | 32.9 | 16.8 | 12.7 | 22.0 |
| Shareholders' equity | 83.0 | 133.0 | 7.3 | -10.9 |
| Net tangible assets | 72.5 | 122.5 | -3.2 | -25.3 |
Avalo Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -51,458,000.0 | -49,056,000.0 | -30,680,000.0 | -26,751,000.0 | — |
| Investing Activities | -81,720,000.0 | 356,000.0 | -133,000.0 | -95,000.0 | — |
| Financing Activities | 14,587,000.0 | 175,849,000.0 | 25,042,000.0 | -14,699,000.0 | — |